Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy
By Hsin-I Chang, M. Yeh. International Journal of Nanomedicine, 2011
791 citations recorded by the source corpus.
Research on liposome formulations has progressed from that on conventional vesicles to new generation liposomes, such as cationic liposomes, temperature sensitive liposomes, and virosomes, by modulating the formulation techniques and lipid composition. Many research papers focus on the correlation of blood circulation time and drug accumulation in target tissues with physicochemical properties of liposomal formulations, including particle size, membrane lamellarity, surface charge, permeability, encapsulation volume, shelf time, and release rate. This review is mainly to compare the therapeutic effect of current clinically approved liposome-based drugs with free drugs, and to also determine the clinical effect via liposomal variations in lipid composition. Furthermore, the major preclinical and clinical data related to the principal liposomal formulations are also summarized.
Subfields: Biomaterials, Molecular Biology, Pharmaceutical Science
View Paper: https://www.semanticscholar.org/paper/496001d5c7443f52fb707c27c34b9640e3f4c70a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomaterials
In Molecular Biology
In Pharmaceutical Science
Citations in the corpus
- Liposomal Formulations in Clinical Use: An Updated Review (2017, background): “PGE-1 is known to act as a potent vasodilator, platelet inhibitor, anti-inflammatory and anti-thrombotic agent [96].”
- Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine (2019, background): “Owing to a facile modulation of their size, hydrophobic/hydrophilic character, low toxicity, and biocompatibility, liposomal nanocarriers still represent the largest group of clinically approved anticancer drug formulations [77, 78].”
- The Smart Drug Delivery System and Its Clinical Potential (2016, background): “To date, a myriad of materials, such as polymers, lipids and inorganic materials, have been developed and served as drug carriers to control the release behavior of payloads [11-16], making the drugs “smart”.”
- Liposomes as nanomedical devices (2015, background): “162,189 EndoTAG-1 plus gemcitabine showed beneficial survival and efficacy in a randomized controlled Phase II clinical trial in advanced pancreatic cancer and triple receptor-negative breast cancer.”